Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,624.70
(
-1.36%
)
US TECH 100
23,767.60
(
-1.51%
)
Dow Jones
46,225.15
(
-1.63%
)
Brent Oil
108.25
(
1.56%
)
Bitcoin
70,881.33
(
-0.51%
)
News Focus
News Focus
Post# of 257257
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

AlpineBV_Miller

Send PM Follow Ignore
Followers 54
Posts 1150
Boards Moderated 0
Alias Born 11/12/2005

AlpineBV_Miller

Re: DewDiligence post# 61684

Monday, 04/21/2008 9:41:32 PM

Monday, April 21, 2008 9:41:32 PM

Post# of 257257
The company says “certain issues” prevented the FDA from evaluating the NDA within the six-month window allotted for Priority Review and hence ALO will resubmit the NDA later.

Oh puh-lease... What is this, silly season for biotech PR? Between INGN, BioVaxID, and this...

Unless otherwise indicated, this is the personal viewpoint of David Miller and not necessarily that of Biotech Stock Research, LLC

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now